Where can acne be treated effectively?

Acne vulgaris is a common, chronic inflammatory disorder of the pilosebaceous unit, primarily affecting adolescents but frequently persisting into adulthood. Effective treatment requires an individualized approach based on acne severity (mild, moderate, or severe), lesion type (comedonal, inflammatory, or nodulocystic), patient age and sex, comorbidities, prior treatment response, and psychosocial impact.

First-line therapy for mild comedonal acne typically includes topical retinoids—such as tretinoin, adapalene, or trifarotene—which normalize follicular keratinization and prevent microcomedo formation. For mild-to-moderate inflammatory acne, combination therapy is preferred: a topical retinoid plus either benzoyl peroxide (BPO) or a topical antibiotic (e.g., clindamycin). BPO is favored over antibiotics alone due to its antimicrobial activity against Cutibacterium acnes and lack of resistance development.

Moderate-to-severe inflammatory or nodulocystic acne often warrants systemic therapy. Oral antibiotics—most commonly doxycycline or minocycline—are used short-term (typically ≤3 months) alongside topical retinoids and BPO to minimize antibiotic resistance. For females with hormonal contributors (e.g., menstrual flares, hirsutism, or polycystic ovary syndrome), combined oral contraceptives containing ethinyl estradiol and a low-androgenic progestin—or spironolactone (50–200 mg/day)—are evidence-based hormonal options.

Isotretinoin remains the gold-standard systemic treatment for severe, recalcitrant, scarring, or psychosocially debilitating acne. It induces prolonged remission in most patients by profoundly reducing sebum production, normalizing keratinization, decreasing C. acnes colonization, and exerting anti-inflammatory effects. Treatment requires strict adherence to the iPLEDGE program in the U.S. (or equivalent national registries) due to teratogenicity and other potential adverse effects.

Adjunctive modalities—including light-based therapies (e.g., blue-light phototherapy, pulsed dye laser), chemical peels (salicylic or glycolic acid), and intralesional corticosteroid injections for acute cysts—may complement pharmacologic therapy but are not standalone solutions for active, widespread disease. Dermatologists are best positioned to diagnose acne subtypes, rule out mimickers (e.g., rosacea, folliculitis, or gram-negative folliculitis), assess scarring, and tailor evidence-based, stepwise management aligned with current guidelines from the American Academy of Dermatology (AAD) and Global Alliance to Improve Outcomes in Acne.